Alpine Immune Sciences Inc (ALPN)
64.60
0.00 (0.00%)
USD |
NASDAQ |
May 02, 16:00
64.60
0.00 (0.00%)
After-Hours: 16:28
Alpine Immune Sciences Cash from Operations (TTM): -79.01M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -79.01M |
September 30, 2023 | -76.83M |
June 30, 2023 | -77.38M |
March 31, 2023 | -75.36M |
December 31, 2022 | -43.75M |
September 30, 2022 | -41.70M |
June 30, 2022 | 4.785M |
March 31, 2022 | 6.172M |
December 31, 2021 | -15.25M |
September 30, 2021 | -9.868M |
June 30, 2021 | -45.39M |
March 31, 2021 | 23.81M |
December 31, 2020 | 30.08M |
September 30, 2020 | 33.76M |
June 30, 2020 | 28.58M |
March 31, 2020 | -33.82M |
December 31, 2019 | -35.35M |
September 30, 2019 | -39.07M |
June 30, 2019 | -35.87M |
Date | Value |
---|---|
March 31, 2019 | -35.21M |
December 31, 2018 | -28.42M |
September 30, 2018 | -24.86M |
June 30, 2018 | -16.59M |
March 31, 2018 | -12.57M |
December 31, 2017 | -16.57M |
September 30, 2017 | -15.91M |
June 30, 2017 | -24.33M |
March 31, 2017 | -27.68M |
December 31, 2016 | -26.26M |
September 30, 2016 | -26.48M |
June 30, 2016 | -24.68M |
March 31, 2016 | -21.32M |
December 31, 2015 | -19.21M |
September 30, 2015 | -16.98M |
June 30, 2015 | -14.37M |
March 31, 2015 | -14.71M |
December 31, 2014 | -14.45M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-79.01M
Minimum
Dec 2023
33.76M
Maximum
Sep 2020
-25.34M
Average
-35.35M
Median
Dec 2019
Cash from Operations (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 3.537B |
Eliem Therapeutics Inc | -20.60M |
Regeneron Pharmaceuticals Inc | 4.594B |
Vera Therapeutics Inc | -92.18M |
Eyenovia Inc | -23.84M |